[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 3 sources · 21 days · First seen · Last updated

BeOne Medicines executive stock transactions

Overview

In July 2026, BeOne Medicines AG CEO John Oyler sold 109,713 American Depositary Shares for approximately $34.6 million. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the transaction, Oyler maintained a controlling ownership position in the oncology-focused biopharma company, holding more than 50.4 million shares through various trusts and an investment LLC.

During the same period, institutional ownership of the stock reached about 48.5%. While investor Siren L. L. C. reduced its stake by 7% in the first quarter, other entities including Cetera Investment Advisers, Rhumbline Advisers, Arrowstreet Capital, Invesco Ltd., and EverSource Wealth Advisors added new positions.

Entities

Andrew Briggs · Evan Pickering · John Oyler · Oncolytics Biotech · AppFolio, Inc.

Timeline

  1. 6 days ago

    [BUSINESS] 3 sources
    Corporate executives and funds execute significant stock transactions

    Recent SEC filings reveal significant stock activity, including large-scale sales by BeOne Medicines CEO John Oyler and insider transactions at AppFolio and Omada Health.

  2. 26 days ago

    [BUSINESS] 3 sources
    BeOne Medicines CEO sells $44.6 M of stock while retaining dominant stake

    BeOne Medicines CEO John Oyler sold $34.6 M of stock but still controls over 50 M shares; Siren L. L. C. cut its stake to $138 M, while other investors added new positions.

Sources

lesgrandsmaitres.fr · mommygearest.com · stocknews.com